<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 27, 1998
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
New Jersey 1-1-432 22-2429994
---------------- --------------- --------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 732-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
- 2 -
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation today announced the
election of Joseph E. Smith to its Board of Directors. Roberts' Board will now
consist of nine members and Mr. Smith is the fifth outside director.
From 1989 until retiring in 1997, Joseph E. Smith served in various
positions with the Warner-Lambert Company including President of Parke-Davis
Pharmaceuticals; President of Shaving Products Division and Member of the
Office of the Chairman. He previously held positions at Johnson & Johnson and
was President of Rorer Pharmaceutical Corporation. Mr. Smith possesses an
extensive background and a wealth of experience in pharmaceutical and consumer
product businesses, both domestic and internationally.
Mr. Smith has served as a board member of the Philadelphia College of
Pharmacy and Science; Alliance for Aging Research; Japan-American
Pharmaceutical Committee; National Association of Chain Drug Stores; and the
Non-Prescription Drug Manufacturers Association.
Mr. Smith received an MBA degree from the Wharton School of the
University of Pennsylvania.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: September 3, 1998 By: /s/ Anthony A. Rascio
------------------------------
Anthony A. Rascio
Vice President
<PAGE>
- 3 -
FORWARD LOOKING STATEMENTS
Certain statements included in Item 5 of this form 8-K are intended to
be, and are hereby identified as, forward looking statements for purposes of the
safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as
amended, and Section 27A of the Securities Exchange Act of 1933, as amended.
The Registrant cautions readers that forward looking statements, including,
without limitation, those relating to the Registrant's future business
prospects, revenues, cost of sales, intangible dispositions and write-offs,
continuing operations and discontinued operations, and liquidity and capital
resources, are subject to certain risks and uncertainties, including, without
limitation, the ability of the Registrant to secure regulatory approval in the
United States and in foreign jurisdictions for the Registrant's developmental
pipeline drugs, the efforts of the Registrant's competitors and the introduction
of rival pharmaceutical products which may prove to be more effective than the
Registrant's products, general market conditions, the availability of capital,
and the uncertainty over the future direction of the healthcare industry, that
could cause actual results to differ materially from those indicated in the
forward looking statements.
